A two-drug combination for treating advanced kidney cancer had sustained and durable clinical benefit in more than five years of follow-up, according to a study published Aug. 1 in Nature Medicine.

CAMBRIDGE, MA / ACCESS Newswire / July 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on its ...

While the fear of cancer looms large in the minds of many, the condition's vague indicators make it hard to know when genuine concern is warranted. Zara McCormick, a project manager from Tameside, was ...

A new mum put her symptoms of fatigue and breathlessness down to pregnancy. But tests finally revealed the devastating ...

As Keytruda generic competition looms larger on the horizon, the company is hoping to reinvest the savings into pipeline ...

Results from 2 studies suggest that adding ICIs to treatment can improve outcomes for patients with resectable HNSCC.

They evaluated pembrolizumab in patients with resectable stage II-IV (M0) cSCC. Patients received 200 mg pembrolizumab every 3 weeks for 4 cycles, followed by 18F-labeled fluorodeoxyglucose-positron ...

A novel triple therapy shows promise for advanced triple-negative breast cancer, offering hope for patients with limited treatment options.

That being said, we’re here with a list of the 10 most profitable new stocks to buy now. We sifted through the Finviz stock screener to compile a list of the top companies that went public in the last ...